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1. Introduction 
Smooth muscle cells constitute the walls of various organs and tubes in the body, 
including the blood vessels, gastrointestinal tract, respiratory tract, bladder, and 
reproductive tracts. The primary function of smooth muscle contraction is to generate 
force, which is utilized to perform many physiological processes such as blood flow and 
blood pressure maintenance, gastrointestinal motility, bronchial diameter regulation, 
bladder evacuation, and fetus expulsion. Smooth muscle contraction is caused by the 
sliding of myosin and actin filaments over each other. Movement of the two types of 
filaments happens when the globular myosin heads protruding from myosin filaments 
attach and interact with actin filaments to form crossbridges. The myosin head first 
attaches to actin together with the products of ATP hydrolysis, performs a power stroke 
associated with release of hydrolysis products, and detaches from actin upon binding 
with a new ATP. The myosin interacts with the actin to convert chemical energy, in the 
form of ATP, to mechanical energy. The coordinated regulation of contraction is a key 
property of the smooth muscle. When the smooth muscle functions normally, it 
contributes to general health and wellness. Contractile abnormalities of the smooth 
muscle are considered to underlie many diseases and disorders, including hypertension, 
vasospasm, diabetes-associated microvascular abnormalities, bronchial asthma, preterm 
labor, urinary incontinence, megacolon, and irritable bowel syndrome. Not surprisingly, 
inadequate contraction and relaxation of smooth muscle may cause the dysfunction of 
these hollow organs, which is usually associated with morbidity and mortality. Hence, 
the precise regulation of smooth muscle contraction is much more important in smooth 
muscles than in striated muscle. The muscle cells can respond to physiological and 
pathological signals from the environment to adapt to the environmental demands. This  
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adaptation is accomplished through signal transduction, which activates factors that 
signal pathways and ultimately lead to muscle contraction or relaxation. The regulation 
of smooth muscle contraction has two main mechanisms: neuromuscular and myogenic. 
In the neuromuscular mechanism, the smooth muscle receives principally neural 
innervation from the autonomic nervous system inside the same tissue, even though the 
central nervous system may be involved in the regulation of smooth muscle contraction. 
The myogenic mechanism, on the other hand, plays a more important role in the 
regulation of smooth muscle contraction. Under this mechanism, smooth muscle cell 
contraction is regulated principally by the mechanical (stretch) activation of the 
contractile proteins myosin and the actin in the intact body. A change in membrane 
potential, brought by the firing of action potentials or by the activation of stretch-
dependent ion channels in the plasma membrane, can also trigger contraction. These 
smooth muscle cells also develop tonic and phasic contractions in response to changes in 
load or length. In addition, the contractile state of the smooth muscle is controlled by the 
hormones, autocrine/paracrine agents, and other local chemical signals. Regardless of the 
stimulus, the smooth muscle cells use crossbridge cycling between the actin and myosin 
to develop force and calcium ions (Ca2+) that serve to initiate contraction in light of the 
current view. The deep mechanism for both myogenic and neuromuscular regulations is 
involved in cell signaling. Because current therapies for disorders and diseases of smooth 
muscles are costly and primarily palliative and do not target the cause of the disease, 
attention is being focused on the detailed understanding of the molecular basis of 
smooth muscle function and regulation and identification of abnormalities 
(dysfunctional proteins and signaling pathways) that lead to contractile pathologies and 
the development of strategies to reverse such abnormalities. The muscle contraction 
regulation mediated by signaling pathways is the key event. In recent years, a variety of 
signaling pathways has been implicated in the regulation of muscle contraction. A 
growing body of evidence shows a fine vista for the research of pathway-mediated 
regulation of the smooth muscle. One of the widely accepted notions is that the increase 
in Ca2+ concentration activates the Ca2+-calmodulin (CaM)–myosin light chain kinase 
(MLCK) pathway and stimulates the 20-kDa myosin light chain (MLC20) 
phosphorylation. The MLC20 phosphorylation at Ser19 causes a conformational change 
that increases the angle in the neck domain of the myosin heavy chain which mobilizes 
the crossbridges and causes the actin thin filament to slide along the myosin thick 
filament. Through an unknown mechanism, this interaction between the myosin and 
actin activates the ATPase activity of the myosin head region and leads to the 
development of a contractile force. Therefore, in theory, the factors that cause the 
inhibition of the MLCK activity and expression, such as calcium deprivation and 
calmodulin inactivation, could abolish consequentially MLC20 phosphorylation and 
smooth muscle cell contraction. However, increasing evidence supports Ca2+-
independent contraction of smooth muscle (Deng et al., 2001; Harnett & Biancani, 2003; 
Ratz et al., 2009). Here, we will describe an MLCK-independent and mitogen-activated 
protein (MAP) kinase-mediated phosphorylation of MLC20.   
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2. Expression and function of MLC20 and MLCK in smooth muscle 
The myosin II (also called conventional myosin), a hexameric protein complex, is composed 
of two identical 200-kD heavy chains and two sets of light chains: the 17-kD light chain 
(MLC17, also known as ELC) and the 20-kD regulatory light chain (MLC20). The exact 
function of the MLC17 is unclear but it may contribute to the structural stability of the 
myosin head along with the MLC20. The MLC20 is a small ring around the neck region of 
heavy chains of myosin and is also known as the regulatory light chain (also called RLC20, 
RLC2, and LC2). It is believed to participate actively in muscle contraction. The MLC20 is 
expressed not only in smooth muscle, but also in cardiac, skeletal, and nonmuscle cells. 
Only the MLC20 in the smooth muscle appears to play a unique role in increasing the actin-
activated ATPase activity. The MLC20 is activated by phosphorylation at multiple serine 
and threonine residues. The phosphorylation of the MLC20 is thought to play a pivotal role 
in regulating muscle contraction.  
Up to now, the MLC20 is the only known physiological substrate of the MLCK. Protein 
kinase C (PKC), CaM-kinase II, Rho-kinase, p21-activated kinase, and p34cdc2 kinase also 
phosphorylate three residues on the N-terminus of the MLC20, Ser-1, Ser-2, and Thr-9. In 
addition, the integrin-linked kinase and ZIP-kinase are reported to phosphorylate the 
MLC20 in the absence of Ca2+, at Ser19 and Thr18, thus activating the myosin activity (Niiro 
& Ikebe, 2001). In vivo phosphorylation of the MLC20 isoforms is accomplished by raising 
free intracellular Ca2+ and subsequent activation of the Ca2+-calmodulin-dependent MLCK. 
Ca2+/calmodulin-dependent MLCK is considered the primary regulator of MLC20 
phosphorylation among potential regulators of MLC20 phosphorylation. The 
dephosphorylation of phosphorylated MLC20 is catalyzed by the myosin light chain 
phosphatase (MLCP), which counters the MLCK that promotes contraction by 
phosphorylating MLC20. The degree of phosphorylation of the RLC depends on the ratio of 
the activities of the MLCK and MLCP. 
The myosin light chain kinase (MLCK or MYLK) is a Ca2+/CaM-activated kinase found in 
smooth, cardiac, and skeletal muscles as well as in many mammalian nonmuscle cells. It is 
a serine/threonine-specific protein kinase that phosphorylates the MLC20 of myosin II. 
There are three isoforms of the MLCK, i.e., smooth muscle (smMLCK, ~130-kDa), skeletal 
muscle (skMLCK, ~220-kDa), and cardiac muscle (cMLCK). The short MLCK (smMLCK, 
~130kDa) is best known as the conventional smooth muscle MLCK. The smMLCK is 
encoded by the mylk1 gene, which expresses three transcripts in a cell-specific manner 
due to the alternate promoters, long MLCK (210- to 220-kDa), short MLCK (130-kDa), and 
the noncatalytic gene product, called telokin. The short smooth muscle MLCK (130-kDa) 
is ubiquitous in all adult tissues with the highest amounts in smooth muscle tissues. Since 
both the short and long MLCK are found in smooth muscles or cultured/embryonic 
smooth muscle tissues, they are called smooth muscle MLCK (smMLCK). The two 
smMLCKs have been extensively described, and their function is to regulate the activity 
of the nonmuscle and smooth muscle myosin II. Here we will deal only with the short 
smooth muscle MLCK (smMLCK).  
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The activation of myosin motors by the MLCK modulates a variety of contractile processes, 
including smooth muscle contraction, cell adhesion, migration, and proliferation. The 
dysregulation of these processes contribute to a number of diseases. It is widely accepted 
that the MLCK phosphorylates the MLC20 of smooth and nonmuscle myosin II in the 
presence of Ca2+ and calmodulin. The phosphorylation of the MLC20 facilitates myosin 
interaction with actin filaments. Once there is an influx of calcium cations into the muscle, 
either from the sarcoplasmic reticulum or, more important, from the extracellular space, the 
contraction of smooth muscle fibers may begin. First, the elevation of the Ca2+ concentration 
in smooth muscles causes the Ca2+ to bind to the calmodulin (CaM). Then, the complex of 
the Ca2+ and CaM (Ca2+/CaM) activates the MLCK, which would phosphorylate the myosin 
light chain (MLC20) at serine residue 19 to generate phospho-MLC20. The phosphorylation 
of the MLC20 enables the myosin crossbridge to bind to the actin filament and allows 
contraction to begin (through the crossbridge cycle). The Ca2+-CaM activates the MLCK by 
reversal of an auto-inhibited state. In contrast, reducing intracellular calcium concentration 
inactivates MLCK but does not stop smooth muscle contraction since the MLC20 has been 
physically modified through phosphorylation. This regulatory model of myosin 
phosphorylation is widely accepted as the intracellular path for the induction of smooth 
muscle contraction.  
However, to a certain extent, this viewpoint about the Ca2+-, MLCK- and MLC20-dependent 
regulatory mechanism is founded on a presumption. Several observations of smooth muscle 
contraction cannot be explained by the mode of phosphorylation (Kohama K & K., 1995). 
For example, when the uterine smooth muscle is subjected to prolonged incubation in a 
Ca2+-free medium, the oxytocin induces the contraction of the muscle without any signs of 
MLC20 phosphorylation (Oishi et al., 1991). Another example is the MLC20 phosphorylated 
in rat embryo fibroblasts, which contains no detectable MLCK (Emmert et al., 2004). In 
addition, these are increasing evidence to support the calcium- and MLCK-independent 
mechanism of MLC20 phosphorylation (McFawn et al., 2003; El-Toukhy et al., 2006; Cho et 
al., 2011). According to the current mode, the expression of the MLCK in tissues/cells is 
necessarily consistent with the MLC20 phosphorylation. However, there has not been any 
report about the consistence between the MLCK expression and MLC20 phosphorylation. 
Herein, we first investigated the consistency between the MLCK expression and phosphor 
MLC20. In the following section we will describe a recent finding, the significant 
inconsistence between MLCK expression, and MLC20 phosphorylation in multiple smooth 
muscles in mice. 
3. Inconsistence between MLCK expression and MLC20 phosphorylation 
According to the current view, the MLCK expression must co-localize with the MLC20 
phosphorylation in cells or tissues. However, by a series of experiments, we recently found 
that phosphorylation (Ser19) of the MLC20 is inconsistent with 130-kDa MLCK expression 
in mouse aorta, bladder, large/small intestines, stomach, and uterus (Deng et al., 2011) 
(Figure.1A and B). 
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Figure 1. Inconsistence between MLC20 phosphorylation and MLCK expression in smooth muscle 
tissues. *in, intestine; †, MLCK expression; ‡, phosphor MLC20. 
In the experiments, fresh smooth muscle tissues were homogenized on ice with pre-cooled 
small glass homogenizers within ice-cold lysis buffer (50 mM Tris, 300 mM NaCl, 3 mM 
EGTA, 0.1 mM sodium orthovanadate, 10% glycerol v/v, 1% NP-40 v/v, 0.3% SDS w/v, 
protease and phosphatase inhibitor cocktails from Sigma Co., Germany, pH 7.6). Twenty 
micrograms of protein were loaded onto 10% SDS-PAGE gels that were subjected to 
electrophoresis in running buffer (BioRad Co., Hercules, CA). The proteins were then 
transferred to the Immobilon-P Transfer Membrane (Millipore Co., MA), followed by 
blocking it with 5% fat-free milk in TBST buffer. The MLCK was detected with a specific 
antibody. After it was washed with 1PBS for three times, the membranes were re-probed 
with antibody anti-phospho MLC20.  The results show that the levels of MLCK expression 
and phosphorylated MLC20 in different smooth muscles from the same mouse are 
markedly different (Figure 1). For instance, the large intestine of mouse 1 contains a high 
level of phosphor MLC20 but the MLCK expression is low. In contrast, the small intestine 
has low phosphor MLC20 but the MLCK expression is high. Besides, the MLCK expression 
and phosphor MLC20 in the same type of smooth muscle tissue are inconsistent among 
different individuals. For example, the large intestine of mouse 1 contains a low expression 
of MLCK and high phosphor MLC20. Conversely, mice 2 and 5 express high levels of MLCK 
in their large intestines but the MLC20 phosphorylation is low. The conspicuous 
inconsistence between the MLC20 phosphorylation and MLCK expression was 
subsequently verified by Western blotting in independent experiments. These interesting 
results cannot be explained by the current regulatory mode. Obviously, they suggest that an 
alternative regulation system may play an active role in the MLC20 phosphorylation. 
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4. Unknown substance(s) other than MLCK phosphorylates MLC20 
Even though some of the smooth muscle does not show phosphor MLC20 bands (Figure 1), 
those tissues still contain the MLC20 because we noticed in subsequent experiments that all 
these frozen lysates had similar levels of phosphor MLC20 after storage in -80C and several 
cycles of freezing and thawing. The MLC20 in some tissues was not visualized by any 
specific antibody against the phosphor MLC20 only because it was not phosphorylated. The 
MLC20 phosphorylation in MLCK-free tissues suggests that unknown molecule(s) may 
phosphorylate the MLC20 in phosphor MLC20-containing tissues.  
Thus, we proposed a hypothesis that something else other than the MLCK phosphorylates 
MLC20 in the smooth muscle tissues, which contain no detectable MLCK. Even though we 
did not know what kind of substance(s) the phosphorylated MLC20 is/are in the phosphor 
MLC20-containing and MLCK-free tissue, it may mobilize the phosphorylative process of 
the MLC20. To test our hypothesis, we designed an unconventional experiment, and added 
a small amount of tissue extract which was freshly prepared from the phosphor MLC20-
containing tissues without any detectable MLCK (extract 2), to another extract that 
contained the unphosphorylated but had no phosphorylated MLC20 and MLCK (extract 1). 
In other words, we theorized that extract 2 is a catalyst and extract 1 is a substrate of extract 
2. By rapid Western blotting assay (with one-hour incubation at room temperature), we 
chose the tissue extract containing the high phosphor MLC20 but no detectable MLCK as a 
catalyst (extract 2), and the one containing no phosphor MLC20 and detectable MLCK as the 
substrate (extract 1). Then, a small amount of exact 2 was added directly into extract 1, as 
shown in Figure 2A. After the one-hour 37C incubation in water, as expected, the added 
extract 2 phosphorylated strongly MLC20 of the extract 1 (lines 2 and 3 in Figure 2A). This 
suggests that high phosphor MLC20 tissue content may have non-MLCK substance(s) that 
induce/s MLC20 phosphorylation.  
To evaluate the further roles of the MLCK and the possible non-MLCK substance(s) in the 
MLC20 phosphorylation, we assayed the effects of the isolated MLCK on MLC20 
phosphorylation (Figure 2B). Firstly, the MLCK was isolated from the fresh smooth muscle 
tissue by the anti-MLCK monoclonal antibody from Sigma Co., following conventional 
immunoprecipitation protocol. Secondly, the isolated MLCK was immediately added to the 
freshly prepared extract 1, which contains unphosphorylated MLC20 but no detectable 
MLCK (line 2 in Figure 2B). In the meantime, a small amount of extract 2 that contains a 
high level phosphor MLC20 but no detectable MLCK was added into the same ‘substrate’ 
extract 1 as a control (line 3). The mixtures were incubated in 37C water for one hour, 
followed by Western blotting assay. Extracts 1, 2 and isolated MLCK were loaded to lines 1, 
5 and 4, respectively, for assays of its own MLCK and phosphor MLC20. No protease and 
phosphatase inhibitor were added into the reaction system. After the membrane was 
washed with PBS for three times, the actin and phospho-MLC20 were simultaneously 
probed by mixture solution of the antibodies against actin and phospho-MLC20 (Membrane 
was not striped by striping buffer because the sizes of the three targeting proteins were 
much different). The results show that the immunoprecipitated MLCK failed to 
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phosphorylate MLC20, while the extract without detectable MLCK phosphorylated MLC20 
of extract 1 contains no detectable MLCK (line 3). Several independent experiments were 
conducted to verify the results. These experiments suggest that MLC20 can be 
phosphorylated in vitro and that non-MLCK substance(s) may trigger the MLC20 
phosphorylation.  
 
Figure 2. Unknown substance(s) in smooth muscle tissue but not immunoprecipitated MLCK induced 
MLC20 phosphorylation. (A) Small amount of extract 2 without MLCK induced MLC20 phosphoryla-
tion of MLC20 in extract 1 (lines 2 and 3). (B) Precipitated MLCK did not induce MLC20 phosphoryla-
tion (line 2). The extract 2 containing no detectable MLCK increased significantly the phosphorylation 
of MLC 20 in extract 1(line 3). MLCK*, MLCK freshly isolated by co-immunoprecipitation from smooth 
muscle tissue; p-MLC20, phosphor MLC20. 
5. Inhibition of MLCK expression and activity do not affect MLC20 
phosphorylation 
According to the  current regulatory model, intracellular calcium ion is the trigger of smooth 
muscle contraction. The contractile initiation, maintenance, and strength are dependent on 
the control of intracellular free Ca2+ level. The canonical excitation-contraction coupling 
pathway is triggered by neural, hormonal or myogenic stimulation to elicit the influx of 
extracellular or intracellular Ca2+ (from the sarcoplasmic reticulum) into the cytosol. The Ca2+ 
binds to calmodulin to form the Ca2+/CaM complex. At an increased level of Ca2+, rapid 
binding of the Ca2+ to CaM occurs and triggers MLCK activation. Once activated, the MLCK 
phosphorylates MLC20 leads to crossbridges cycling and generation of the contractile force. 
Therefore, several factors may affect the MLC20 phosphorylation, including expression of 
the MLCK gene, MLCK activity, free Ca2+ concentration, and CaM activity. The following 
experiments were designed to access the effects of these factors on the role of the MLCK in 
MLC20 phosphorylation: 1) using siRNA to knockdown the MLCK expression in human 
bladder smooth muscle (hBSM) cells, 2) inactivating the MLCK by inhibitors of calmodulin 
and MLCK, and 3) depriving the calcium ion of cultured hBSM cells. 
We first investigated the effect of alteration in MLCK expression on the MLC20 
phosphorylation. To inhibit the MLCK expression, the siRNA against MLCK (from Santa 
Cruz Biotechnology Inc.) was transfected with Lipofectamine 2000 into cultured hBSM cells 
at a cell density of 40-50% confluence, which were isolated from the peri-cancer tissue of a 
bladder cancer patient. Only lower than seventh passage primary cells were used for 
experiments. Two days after transfection, cells were harvested for Western blotting.  MLCK, 
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pan-actin and phosphor MLC20 were detected by specific antibodies. Western blotting 
analysis showed that no significant alteration of MLC20 phosphorylation level was observed 
while the MLCK expression was knocked down (Figure 3A). Together with the data about 
the expression of MLCK and MLC20 phosphorylation from mice, this experiment provides 
further proof that MLC20 phosphorylation is independent of MLCK gene expression.  
Equally vital to the MLCK gene expression, the MLCK activity or activation may contribute 
to its functions. Then, the subsequent experiments were designed to study the effects of the 
MLCK activity on the MLC20 phosphorylation. The MLCK and its upstream molecule, the 
CaM, were directly inactivated by the corresponding commercial inhibitory peptides (EMD 
Chemicals Inc., NJ) in both permeabilized or unpermeabilized hBSM cells (Figure 3B, C) and 
mouse smooth muscle extracts (Figure 3D). The MLC20 phosphorylation was examined by 
Western blotting. In addition, ethylene glycol tetraacetic acid (EGTA), a Ca2+ chelating agent, 
was added into the medium to prevent the formation of Ca2+/CaM complex in cultured 
hBSM cells (Figure 3B and C). CaM and MLCK inhibitory peptides were added into 
mixtures of smooth muscle extracts 1 and 2, in which small amount of extract 2 was able to 
phosphorylate MLC20 of extract 1 (shown in figure 2). After one-hour incubation at 37C, 
pan-actin and phosphor MLC20 were assayed by Western blotting. Likewise, none of the 
inhibitors of the MLCK and CaM, and EGTA inhibit the MLC20 phosphorylation in both 
cultured hBSM cells and tissue extracts. 
 
Figure 3. Inhibition of MLCK expression and activity does not block MLC20 phosphorylation. (A) 
siRNA-mediated MLCK knockdown did not inhibit MLC20 phosphorylation. (B and C) Inhibitors of 
CaM and MLCK and EGTA did not suppress MLC20 phosphorylation in permeabilized and unperme-
abilized cells. (D) Neither CaM nor MLCK inhibitors blocked MLC20 phosphorylation in smooth mus-
cle extracts.  
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Putting the data together, we firmly believe that an alternative mechanism plays an 
important part in the regulation of MLC20 phosphorylation. This potential regulatory 
mechanism is MLCK-independent. 
 
Figure 4. Two main pathways involved in regulation of smooth muscle cell contraction and migration. 
The contractile response is initiated by a rapid and transient rise in intracellular Ca2+, followed by a 
Ca2+-calmodulin interaction, the MLCK activation to initiate phosphorylation of the MLC20 and there-
fore contraction and cell migration (the blue). Agonists (such as ET-1) bind to serpentine receptors on 
the membrane of the smooth muscle cells to activate the RhoA/Rho kinase signaling pathway, which 
inactivates the MLC phosphatase (MLCP) by phosphorylation, and resulted in increased unphosphory-
lated MLCP and sustained smooth muscle contraction (the green). GAP, GTPase activating protein; 
GEF, GDP/GTP exchange factor. 
6. MAP kinase pathways and functions in smooth muscle cells 
After we verified the MLCK-independent regulation of MLC phosphorylation, we were 
interested in searching for the non-MLCK mechanism that may function as the trigger of 
MLC20 phosphorylation. The cell signaling pathways would be most likely to address this 
intractable issue. In recent years, a multitude of signaling pathways has been suggested to 
regulate the smooth muscle contractility. However, these pathways can be broken down 
into two major pathways (Figure 4): the calcium–calmodulin signalling pathway and 
Rho/Rho-kinase pathway.  The former, the Ca2+/CaM pathway, regulates smooth muscle 
contraction by the binding of increased intracellular calcium ion with CaM, which activates 
the MLCK. The MLCK phosphorylates the MLC20 at the neck of the myosin heavy chains. 
The phosphorylation increases the ATPase activity and thereby produces contraction. In the 
Rho/Rho-kinase pathway, the Rho A-GTP, activated by multiple stimuli, activates the Rho 
kinase (also known as Rok or Rock). The activated kinase phosphorylates the myosin 
phosphatase and therefore modulates the MLC20 phosphorylation. 
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In the following sections, we will describe a MAP kinase-mediated phosphorylative 
mechanism of MLC20. 
 
Figure 5. The main components of the three MAP kinase pathways. MAP kinase cascade is typically 
composed of four kinases that establish a sequential activation pathway comprising a MAP kinase 
kinase kinase kinase (MAP4K), MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAP2K), and 
MAP kinase (MAPK). Extracellular/intracellular stimuli activate MAP4K, MAP3K, MAP2K and MAPK 
sequentially, leading to the multiple biological effects.  
MAP kinases (MAPKs) comprise a family of serine threonine kinases, which include three 
major sets of kinases: extracellular signal-regulated kinases (ERK1 and ERK2), c-Jun amino-
terminal kinase/stress-activated protein kinases (JNKs), and p38 MAPKs (Figure 5). These 
kinases constitute three major discrete cascades and serve as focal points in response to a 
variety of extracellular stimuli. Members of all three MAPK families, the ERK, JNK, and the 
p38 MAPKs, are expressed in various types of tissues and cells, including smooth muscles. 
6.1. ERK pathway 
The best-characterized members of the MAPK family are ERK1 and ERK2, also known as 
p44 MAPK and p42 MAPK, respectively. The canonical ERK cascade comprises Ras, Rafs, 
MEK1/2, ERK1/2 and several MAPK-activating protein kinases (MAPKAPK, such as EIk-1, 
Sap1a and c-Fos). ERK1 and ERK2 are expressed to various extents in all tissues, including 
various types of smooth muscle. ERK1/2 is distributed throughout quiescent cells, but upon 
stimulation, a significant population of ERK1/2 accumulates in the nucleus. Immediate 
upstream kinases that activate ERK cascade are mitogen-activated protein kinase kinase 1/2 
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(MEK1/2). The ERK is activated by a large variety of diverse extracellular stimuli, including 
growth factors, cytokines, virus infection, transforming agents, and carcinogens. Activated 
ERK1/2 phosphorylate numerous substrates, including various membrane proteins 
(CD120a, Syk, and calnexin), nuclear substrates (SRC-1, Pax6, Elk-1, MEF2, c-Fos, c-Myc, 
and STAT3), cytoskeletal proteins, and several MAPK-activated protein kinases (MKs), and 
MAPK-interacting kinases(MNKs). As a consequence of the activation, ERK pathway 
regulates many distinct and even opposing cellular processing, including proliferation, 
differentiation, metabolism, morphology, survival and even apoptosis.  
ERK pathway may be involved in regulation of contraction, migration and proliferation of 
smooth muscle cells. PD-098059, a specific inhibitor of MAP kinase kinase (MEK1/2, the 
upstream of ERK1/2), reduced vascular smooth muscle contraction and increase in blood 
pressure induced by Ang II and phenylephrine, perhaps by inhibiting ERK1/2 activation 
(Escano et al., 2008) and airway smooth muscle contraction by isoprenaline (Lelliott et al., 
2012). Direct inhibition of ERK1/2 by U-0126 attenuates Ang II- and isoprenaline-induced 
contraction of bronchial smooth muscle (Sakai et al., 2010; Lelliott et al., 2012). Similar role of 
ERK1/2 are also observed in other smooth muscle (cells) (Jeong et al., 2011). However, some 
reports show that the inhibitors of ERK and its upstream do not affect vascular smooth 
muscle contraction (Do et al., 2009; Bauer et al., 2011; Sathish et al., 2011). Thus, this role of 
ERK in regulation of smooth muscle contraction is not universal, or even controversial. 
The biological process of cell migration is similar to that of muscle cell contraction. The 
functional role of ERK in the regulation of smooth muscle cell migration is reported by a 
large number of articles (Aitken & Bagl, 2001; Kavurma & Khachigian, 2003). Many reports 
about the regulatory model of ERK1/2 in smooth muscle cell migration are consistent, even 
though it is not entirely clear how ERK activation promotes smooth muscle cell motility. For 
example, inhibition of ERK by inhibitor and antisense oligonucleotide blocks smooth muscle 
migration (Graf et al., 1997; Gerthoffer, 2007). Our study confirmed role of ERK1/2 in smooth 
muscle cell migration by blocking movement by PD-098059(Deng et al., 2011). In addition, 
Raf-1 kinase, the upstream molecule of MEK1/2 that activates ERK1/2, may be involved in 
regulation of smooth muscle contraction (Sathishkumar et al., 2010). 
6.2. p38 pathway 
The p38 cascade is composed of MEKK3, MKK3/4/6, p38 and several MAPKAPKs (EIk-1, 
CHOP, ATF2 and MEF2A). The p38 family includes four splice variants: p38α, p38, 
p38γand p38δ. Like the rest of MAP kinases, p38 are ubiquitously expressed in various 
types of tissues, including various smooth muscle cells. Two main MAPKKs, MEK3 and 
MEK6, function as the upstream molecules of p38, which are known to activate p38. In 
addition, MEK4, an upstream kinase of JNK, can aid in the activation of p38α and p38δ in 
specific cell types. The p38 MAPK cascade is activated by numerous promigratory stimuli, 
including platelet-derived growth factor (PDGF), Ang II, S1P, and thrombin. This kinase is 
also responsive to a wide range of environmental stresses, such as ultraviolet irradiation, 
heat shock, osmotic shock, as well as response to inflammatory cytokines, but less by serum 
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and growth factors. Substrates of p38 in vivo include transcription factors (ATF2, MEF2C), 
the RNA binding protein tristetraprolin, and several protein kinases, such as MAPKAP 
kinases 2, 3, and 5. The p38 signaling has been implicated in cellular responses including 
inflammation, cell cycle, cell death, development, cell differentiation, senescence, and 
tumorigenesis. Because p38 MAPKs are key regulators of inflammatory cytokine expression, 
they appear to be involved in many human diseases such as asthma and autoimmunity. 
The p38 MAPKs may participate in multiple processes in smooth muscle cells including 
contraction, oxidative stress signaling, and cytokine synthesis . Contraction induced by 
some but not all agonists depends on p38 activity. SB203580, the specific inhibitor of p38, 
blocks spontaneous and agent-induced smooth muscle contraction (Lee et al., 2007; Barona et 
al., 2011). Besides, by using SB203580 and siRNA, researchers have demonstrated that p38 is 
involved in regulation of smooth muscle cell migration (Mugabe et al., 2010).  
6.3. JNK pathway 
The JNK cascade comprises generally MAP-ERK kinase kinase-1 (MEKK1), MKK4/7, JNKs 
and MAPK-activated C-Jun, JunB and ATF2. JNK family, encoded by three genes, jnk1, jnk2, 
jnk3, includes three main spliced forms, JNK1, -2, and -3, also known as SAPK, SAPK, and 
SAPK, respectively. JNK1 and JNK2, are believed to be expressed in every cell and tissue 
type, whereas the JNK3 protein is found primarily in brain (Bode & Dong, 2007). JNK 
activation is much more complex than that of ERK1/ERK2 owing to inputs by a greater 
number of MAP4Ks and MAP3Ks. This diversity of upstream messages allows a wide range 
of stimuli to activate this MAPK pathway, including UV and -irradiation, protein synthesis 
inhibitors (anisomycin), hyperosmolarity, toxins, ischemia/reperfusion injury in heart 
attacks, heat shock, anticancer drugs (cisplatinum, adriamycin, or etoposide), ceramide, 
peroxide, and inflammatory cytokines such as TNF. The activated JNKs translocate to the 
nucleus where they phosphorylate the effector molecules. A well-known substrate for JNKs 
is the transcription factor c-Jun. Besides, several other transcription factors have been shown 
to be phosphorylated by the JNKs, such as ATF-2, NF-ATc1, HSF-1, c-Myc, p53, STAT3, 
DPC4/ SMAD4/MADH4. Some non-transcription factors can also be regulated by JNKs, 
such as Bcl-2, paxillin, and Bcl-xL. The dual role of JNK in both apoptotic and survival 
signaling pathways indicates that the functional role of JNK is complex. JNKs are involved 
in various physiological and pathological processes, such as apoptosis, neurodegeneration, 
neural development, cell differentiation and proliferation, inflammation, cytokine 
production and regulation of responses to stimuli. 
Compared with ERK and p38 MAPKs, less is known about the role of JNK MAPKs in 
contraction and migration of smooth muscle cells. The chemical inhibitors of JNK family 
members are less selective than MEK (then ERK1/2) and p38 MAPK inhibitors and therefore 
somewhat less useful for definitive studies of kinase action in cells. However, recent 
evidences support an important role for JNK in regulation of airway smooth muscle 
contraction (Lei et al., 2011). SP600125, a JNK inhibitor, attenuates vascular smooth muscle 
contraction and human prostate smooth muscle induced by norepinephrine and 
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phenylephrine (Lee et al., 2006; Strittmatter et al., 2012). In addition, overexpression of an 
inactive mutant of JNK partially inhibits migration induced by PDGF-BB and Ang II (Ohtsu 
et al., 2005). The mutant may attenuate natural JNK activity by interfering its binding to the 
up- and down-stream molecules. Besides, SP600125 inhibits smooth muscle migration 
(Kavurma & Khachigian, 2003). 
7. Regulation of MAP kinase pathways on MLC20 phosphorylation 
By using the MAPK inhibitors and adenoviral overexpression, we found a MAP kinase 
pathway-mediated regulatory mechanism of MLC20 phosphorylation. 
7.1. Inhibition of MAP kinase pathways increases phosphorylation level of 
MLC20 
Research on the role of the ERK, p38 MAPK, and JNK is facilitated by effective and 
relatively selective small molecule inhibitors. We first used the p38, JNK, and ERK inhibitors 
to access the effects of MAP kinase signaling on MLC20 phosphorylation in cultured hBSM 
cells (Figure 6A).  
The SB203580, BIRB 796, SB 202190, and VX-702 have inhibitory effects for the p38 kinase 
but only the SB 203580, a specific inhibitor of p38α and p38β isoforms, is widely used for the 
p38 function-related studies. The half maximal inhibitory concentration (IC50) values 
recommended by the manufacturer are 50 and 500 nM for the p38αand p38β, respectively. 
The concentration ranges used in published reports are 10–50 M (Kramer et al., 1996; 
Fatima et al., 2001; Kim et al., 2002). The JNK inhibitors include the SP600125, JNK inhibitor 
I (a peptide), JNK inhibitor IX, and JNK inhibitor VIII. The SP600125, a JNK inhibitor for 
three isoforms of JNKs, is often used to inhibit JNKs in most studies. The recommended 
IC50 values are 40 nM for JNK-1 and JNK-2, and 90 nM for JNK-3. The concentration ranges 
used by most previous researchers are 10–30 µM (Renlund et al., 2008). The recently used 
concentration is 20 µM (Takahashi et al., 2011). The ERK inhibitors include the PD98059, 
ERK Inhibitor II (C18H13N7), U0126, and inhibitory peptide. It is a 13-amino acid peptide that 
corresponds to the N-terminus of MEK1 and functions as a specific inhibitor of ERK 
activation. The IC50 recommended by the manufacturer is 2.5 µM. Different concentrations 
such as 10, 20, 40, and 50 µM were used in previous researches (Mathur et al., 2004; Monick 
et al., 2008). The concentration of 60 µM was used in our studies. Considering the difficulty 
to transport a peptide across a cell membrane, we permeabilized cells before the ERK 
inhibitor treatment, even though the inhibitor peptide is cell-permeable.  
In this study, the cultured hBSM cells were exposed to 30 M of SB203580 (a p38 inhibitor), 
SP600125 (a JNK inhibitor), and 60 M of ERK inhibitory peptide for 40 min. Cells for ERK 
inhibition were previously permeabilized (Deng et al., 2011). Proteins of cell lysates were 
separated by SDS-PAGE electrophoresis and then transferred to PVDF membranes. Actin, 
phosphor MLC20 and MLCK on the same membrane were detected. Inhibition of MAP kinase 
activity increased MLC20 phosphorylation (Figure 6A). To minimize the effects of the 
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quantitative difference in protein loading on experimental judgment in Western blotting assay, 
we always incubated membranes with mixed primary antibodies against pan-actin and 
phosphor MLC20, followed by incubation with corresponding and different second antibody 
after PBS washing. The actin gene is a housekeeping gene, which is expressed invariably in 
various cells/tissues usually at different treatments. The pan-actin bands can show us how 
much protein is loaded in the wells of SDS-PAGE gels. Then, the membrane was re-probed 
with specific antibody against the MLCK. Unexpectedly, all of the three MAP kinase inhibitors 
appear to increase the phosphor MLC20 level (Figure 6A), especially treatments by the SB 
203580 and SP600125 in lines 2–3. The MLCK expression was not altered when the phosphor 
MLC20 level increased due to the MAP kinase inhibitor treatment. 
 
Figure 6. Negative regulation of MAP kinase pathway on MLC20 phosphorylation. (A) All of p38, JNK 
and ERK inhibitors raised phosphorylation level of MLC20. (B)Activation of MAP kinases by adenovi-
rus-mediated overexpression of MEKK1 inhibited significantly MLC20 phosphorylation (line 3). MAPK 
inhibitors counteracted inhibition of MEKK1 on MLC20 phosphorylation (line4~6). (C, D) The level of 
MLC20 phosphorylation increased with JNK and p38 inhibitors in hBSM cells. (E, F) MLC phosphoryla-
tion decreased with MEKK1-viral doses. P-MLC20, phosphor MLC20; SB, SB203580; SP, SP600125; adv, 
adenovirus. 
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7.2. Activation of MAP kinase pathways inhibits MLC20 phosphorylation 
Contrary to the MAP kinase-inhibition experiment (Figure 6A), the activity of the MAP 
kinases was to be increased in this experiment. The activity of the MAP kinase in quiescent 
cells is relatively low (Graf et al., 1997; Pizon & Baldacci, 2000; Hatton et al., 2003; 
Kuramochi et al., 2004; Mackeigan et al., 2005), and we observed low activation of MAP 
kinases in the hBSM cells used in this study. It is difficult to observe the alteration of the 
MAP kinase activity during a change of MLC20 phosphorylation. Thus, we increased the 
intracellular levels of the phosphor MAP kinases by adenovirus-mediated overexpression of 
active human MAP-ERK kinase kinase-1 (MEKK1), the upstream molecule of MAP kinases 
in hBSM cells.  
The generation of MEKK1-containing adenovirus is described in brief as follows. To 
overexpress MEKK1, an HA-tagged 4.9-kb cDNA for active human wild-type MEKK1 was 
cloned at the downstream of cytomegalovirus (CMV) promoter of pAdtrack, a shuttle vector 
that transports target gene MEKK1 to the viral plasmid. To prepare the MEKK1-containing 
viral DNA, the shuttle vector was recombined with the adenoviral DNA in bacteria. Then, 
the recombinant adenoviral plasmid was used to produce the adenovirus in packaging cells 
following conventional protocol for adenovirus preparation. Two control adenoviruses were 
prepared in the same procedure but human MEKK1 was replaced by the -galactosidase 
(LacZ) or green fluorescent protein (GFP). The control virus helped us to distinguish the 
MEKK1 effects from that of non-MEKK1 virus infection. After the amplification, the viruses 
were titrated by the agarose overlay plaque assay. 
The viral infection efficiency in the cultured hBSM cells was examined by observing the 
percentage of the GFP-positive living cells under a fluorescence microscope. The viral 
expressive efficiency of MEKK1 was assayed in an independent experiment by Western 
blotting using an antibody against the HA-Tag (Deng et al., 2011). The exogenous 
MEKK1 activity expressed by the adenovirus was estimated by its capacity to activate 
the downstream molecules, including the JNK, ERK, and p38. These results show that the 
infection efficiency of the adenoviruses in the cultured hBSM cells reached up to 99% 
(the cell density was 70% when infected). The MEKK1 expressed by the adenovirus 
activated strikingly JNK1 and JNK2. In the meantime, it also activated the ERK1 and p38 
kinase to a lower extent. Then, the MEKK1 adenovirus was used for the evaluation of the 
roles of the MAP kinase on MLC20 phosphorylation. When the cell density was between 
60–70%, the hBSM cells in 6-well plates were infected with the MEKK1 and the control 
viruses at different doses (Deng et al., 2011). Three days after infection, the cells were 
harvested for Western blotting. The experimental results show that the MEKK1 
adenovirus infection inhibited the MLC20 phosphorylation significantly (line 3 in Figure 
6B). The inhibition of the MAP kinase pathway for the MLC20 phosphorylation is 
already hinted in Figure 6A but the extent of inhibition is beyond our expectation. 
Apparently, the inhibitory efficiency depends on viral infection efficiency, expressive 
capacity of MEKK1 adenovirus, and activating ability of MEKK1 for the downstream 
molecules. 
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In addition, we set up other treatments, using MAP kinase inhibitors to counteract the 
activation of the MEKK1 for the MAP kinases so that we could evaluate more accurately 
the role of the MEKK1-activated MAP kinase pathway in the regulation of the MLC20 
phosphorylation. If it is true that the MEKK1 regulates negatively the MLC20 
phosphorylation, the MAP kinase inhibitors would augment the MLC20 phosphorylation 
through suppression of the activity of the MEKK1 downstream molecules. As expected, 
the MAP kinase inhibitors neutralized the inhibition of the MEKK1 adenovirus on the 
MLC20 phosphorylation (lines 4–6 in Figure 6B). Likewise, the actin bands are detected 
to show a similar amount of loaded proteins. Obviously, the experimental results and 
even conclusions depend on the balance between the viral doses and inhibitor 
concentrations. A relatively low-concentration inhibitor may not affect the role of a 
relatively high-dose infection of MEKK1 adenovirus in MLC20 phosphorylation, and 
vice versa. 
The dose-response relationship is a mathematic relationship between the dose and the 
organism's reaction to the dose. It describes the change in reaction or effect on an organism 
caused by differing levels of doses. Herein, we used dose-gradient methods to provide 
additional evidence that the MLC20 phosphorylation is regulated by the MAP kinase 
pathways. In the studies, the hBSM cells were exposed to different concentrations of the 
MAP kinase inhibitors for 40 minutes, followed by Western blotting assays for the phosphor 
MLC20. The results show that phosphor MLC20 level increases with the doses of inhibitors 
(Figure 6C and D, ERK inhibitor not shown) (Deng et al., 2011). A similar method was used 
to examine the effects of the MEKK1 at different infection doses (i.e., pfu/cell) on the MLC20 
phosphorylation. The phosphor MLC20 decreased with doses of the MEKK1 adenovirus 
(Figure 6 E and F). 
At this point, our experiments have demonstrated the negative regulation of MAP kinase 
pathway on the MLC20 phosphorylation. 
8. Suggestions for the future investigation 
The role of the MLC20 phosphorylation in contraction needs to be reassessed, even though it 
is accepted widely as a trigger of muscle contraction. A number of experiments have already 
verified the role of the MAP kinase pathway in the migration of different cell types and 
smooth muscle contraction. Therefore, according to current views, it is reasonable to assume 
that the MAP kinases would phosphorylate the MLC20, either via one or more enzymes. 
However, a series of experiments above showed the negative regulation of the MAP kinase 
pathways on the MLC20 phosphorylation. Because of conflict between our conclusion and 
current views about the mechanism of the MLC20 phosphorylation, we subsequently 
carried out a preliminary experiment to explore the synchrony between the cell migration 
and MLC20 phosphorylation. The migrating cells were fixed immediately and the phosphor 
MLC20 inside cells was immunostained with a specific antibody. However, we did not see a 
difference in the fluorescence intensity of the phosphor MLC20 between the migrating and 
quiescent cells (Deng et al., 2011). 
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In addition, when laboratory animals are killed, the muscle is usually relaxed, or rapidly 
relaxed in seconds (except for some smooth muscles). Because muscle contraction and 
relaxation are rapid, the MLC20 phosphorylation and dephosphorylation are also very fast, 
especially in the skeletal muscle. Even for smooth muscles, the muscle contraction and 
relaxation, such as the bladder emptying by detrusor and relaxation of tracheal/bronchial 
smooth muscle elicited by agents, may be fast. In one word, the MLC20 is phosphorylated in 
contracting muscle but unphosphorylated in relaxed muscle, and the transformation 
between the phosphorylation and nonphosphorylation is rapid. The muscle samples used in 
a lot of published articles for the MLC20 phosphorylation are almost in non–contracting 
status. However, those reports show that the phosphorylated MLC20 in various types of 
muscles are actually in relaxed state. Besides, a lot of data from different laboratories 
demonstrate that the MLC20 is phosphorylated strongly in cultured cells. As we all know, 
cells in culture dishes stop moving and are considered quiescent cells when they reach a 
high density like 90%. This suggests that the MLC20 is heavily phosphorylated in 
nonmigrating cells. Up to now, there is no direct evidence to support that the MLC20 
phosphorylation triggers muscle contraction. 
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